Showing 2441-2450 of 2527 results for "".
- Konan Medical USA Acquires objectiveFIELD Objective Perimeterhttps://modernod.com/news/konan-medical-usa-acquires-objectivefield-objective-perimeter/2479795/Konan Medical USA has acquired objectiveFIELD, an FDA-cleared device designed to assess the human visual field in an objective and non-contact manner. The device was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machine
- EMA Accepts Drug Application for Regulatory Approval of Rhokiinsa (Rhopressa)https://modernod.com/news/ema-accepts-drug-application-for-regulatory-approval-of-rhokiinsa-rhopressa/2479802/Aerie Pharmaceuticals reported that the European Medicines Agency (EMA) has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated IOP in patients with open-
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that
- Alcon Introduces Enhanced WaveLight Refractive Suitehttps://modernod.com/news/alcon-introduces-enhanced-wavelight-refractive-suite/2479821/Alcon unveiled software and hardware enhancements to the WaveLight Refractive Suite designed to provide surgeons and patients a more comfortable and efficient LASIK experience. The new platform offers a modernized user interface, ergonomic design, and expanded equipment color options. “Al
- Chiropractic Treatment and Vision Loss: Examining the Connectionhttps://modernod.com/news/chiropractic-treatment-and-vision-loss-examining-the-connection/2479828/Many Americans visit chiropractors to address pain, often without informing their physicians. And they might not consider eye complications that could result, says Yannis Paulus, MD, a retina specialist at the University of Michigan Kellogg Eye Center. The energetic thrusts and rota
- Omeros Announces Reinstatement of Pass-Through Status for Omidriahttps://modernod.com/news/omeros-announces-reinstatement-of-pass-through-status-for-omidria/2479831/Omeros announced reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The pass-through status is effective as of October 1, 2018.
- CooperVision Introduces Online Training to Help ECPs Upgrade Contact Lens Patients to Silicone Hydrogel 1-Day Lenseshttps://modernod.com/news/coopervision-introduces-online-training-to-help-ecps-upgrade-contact-lens-patients-to-silicone-hydrogel-1-day-lenses/2479834/To help eye care professionals grow their silicone hydrogel 1-day contact lens business, CooperVision is unveiling a new, comprehensive online training program that can be completed at any place and time. The web-based training and on-demand webinar focus on teaching practitioners and staff how t
- PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceuticalhttps://modernod.com/news/peptidream-announces-drug-discovery-and-development-agreement-with-santen-pharmaceutical/2479839/PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company, announced that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig
- Bascom Palmer Treats First US Patient in Nightstar Gene Therapy Clinical Trial for X-Linked Retinitis Pigmentosahttps://modernod.com/news/bascom-palmer-treats-first-us-patient-in-nightstar-gene-therapy-clinical-trial-for-x-linked-retinitis-pigmentosa/2479869/A patient with X-linked retinitis pigmentosa (XLRP) is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. On August 23, Julio Adorno Nieves, 23, of Puerto Rico, became the first U.S. patient to